What Vaylen actually is
[Vaylen](/brands/vaylen) is a direct-to-consumer telehealth platform. It connects patients with licensed clinicians who can prescribe semaglutide and tirzepatide, the same active ingredients found in Ozempic/Wegovy and Mounjaro/Zepbound. Everything ships by mail through compounding pharmacies, following an online health assessment.
Not a pharmacy. Not a drug manufacturer either. Vaylen's actual role is the intake, clinician matching, and ongoing coordination layer that sits between a patient and the compounding pharmacy that fills the prescription.
The three products on offer
Vaylen offers a [semaglutide injectable](/brands/vaylen), a [tirzepatide injectable](/brands/vaylen), and a [semaglutide oral tablet](/brands/vaylen), the last being a needle-free option using the same active ingredient as the injectable version. All three require the same clinician review process before dispensing.
For readers weighing which of the two active ingredients might suit them, our semaglutide vs tirzepatide comparison breaks down the mechanism and trial-outcome differences between the two independent of any specific telehealth provider.
Pricing, broken down
All three products were priced from $83.25 per month on a 12-month commitment plan at the time of this review. Semaglutide alone was also available at a higher $224 per month rate on a shorter-term basis. Longer commitments simply cost less per month, a common pattern across telehealth GLP-1 platforms.
Read the actual plan terms. The headline figure a platform advertises often reflects the longest available commitment, not what a first-time patient actually pays on a shorter trial period.
| Product | Starting price (12-month plan) | Format |
|---|---|---|
| Semaglutide Injectable | $83.25/month | Weekly injection |
| Tirzepatide Injectable | $83.25/month | Weekly injection |
| Semaglutide Oral Tablet | $83.25/month | Daily dissolvable tablet |
The clinician process and refund policy
Vaylen states that every prescription follows an individual clinician review of the patient's submitted health information, rather than an automated approval, and that a full refund is issued if that review results in a non-approval. We verified this is the vendor's stated policy; we did not test it directly by submitting an application ourselves.
The platform positions itself around "real doctors, real outcomes," emphasizing individual review over a purely automated intake, a distinction worth understanding given how much telehealth GLP-1 competition has emerged in this space over the past few years.
What we could and couldn't verify
We confirmed the pricing structure directly from Vaylen's own site, including the per-month figures across all three products and commitment lengths. We also confirmed the marketed average weight-loss figures, roughly 15% for semaglutide and roughly 20% for tirzepatide, are broadly consistent with the published trial data for each drug at the population level, discussed in more depth in our semaglutide vs tirzepatide breakdown.
What we could not verify: Vaylen's own specific patient outcomes data, the identity of the specific compounding pharmacy or pharmacies it works with, or the actual clinician review process from the inside, since that would require submitting a real application.
Vaylen vs other GLP-1 telehealth options
Vaylen is one of several telehealth platforms offering compounded GLP-1 medications; ReadyRx is another we've reviewed separately, offering a broader category range beyond just GLP-1s, including NAD+ and sermorelin. Neither platform sells branded Ozempic, Wegovy, Mounjaro, or Zepbound directly, since both work through compounding pharmacies rather than the original manufacturers.
If cost, plan length, and the specific active ingredient options matter most to your decision, comparing the current pricing and product range across a couple of platforms before committing is worth the extra ten minutes.
Who this is and isn't for
Vaylen is relevant to adults considering GLP-1 medication for weight management who prefer a telehealth process over an in-person visit, and who are comfortable with a compounded rather than branded product. It is not appropriate for anyone with a personal or family history of certain thyroid cancers, a contraindication that applies to this entire drug class regardless of which telehealth platform is used.
This review describes what the service offers and what we could verify. It is not a recommendation to use it, and nothing here is medical advice.
